Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Walsh

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials GroupChristine I Chen, C Tom Kouroukis, Darrell White, et al.
Investigational New Drugs|May 4, 2004
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanomaSusan Burdette-Radoux, Richard G Tozer, Reinhard C Lohmann, et al.
Leukemia & Lymphoma|October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancerAnthony W Tolcher, Leonard Reyno, Peter M Venner, et al.
BMC Geriatrics|December 5, 2024
The Mobility and Voiding Exercises in Older Women with Urinary Incontinence (MoVEonUp) randomized controlled trial: study protocol and rationaleUduak U Andy, Diane K Newman, Jean F Wyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Leukemia & Lymphoma|April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials GroupRena Buckstein, John Kuruvilla, Neil Chua, et al.
Investigational New Drugs|December 6, 2006
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumoursTara Baetz, Elizabeth Eisenhauer, Lillian Siu, et al.
Investigational New Drugs|December 21, 2010
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancerDaniel J Renouf, Malcolm J Moore, David Hedley, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials GroupChristine I Chen, C Tom Kouroukis, Darrell White, et al.
Investigational New Drugs|May 4, 2004
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanomaSusan Burdette-Radoux, Richard G Tozer, Reinhard C Lohmann, et al.
Leukemia & Lymphoma|October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancerAnthony W Tolcher, Leonard Reyno, Peter M Venner, et al.
BMC Geriatrics|December 5, 2024
The Mobility and Voiding Exercises in Older Women with Urinary Incontinence (MoVEonUp) randomized controlled trial: study protocol and rationaleUduak U Andy, Diane K Newman, Jean F Wyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Leukemia & Lymphoma|April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials GroupRena Buckstein, John Kuruvilla, Neil Chua, et al.
Investigational New Drugs|December 6, 2006
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumoursTara Baetz, Elizabeth Eisenhauer, Lillian Siu, et al.
Investigational New Drugs|December 21, 2010
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancerDaniel J Renouf, Malcolm J Moore, David Hedley, et al.
Pageof 4